Did you mean “Jardiance” and “LOE” (loss of exclusivity)?
“Jardiance” is the brand name for empagliflozin, an SGLT2 inhibitor. People often search “Jardiance LOE” to figure out when the drug’s market exclusivity ends—i.e., when generic or biosimilar competition may start.
However, “loe” alone doesn’t specify whether you mean:
- Loss of patent exclusivity (patent expiration), or
- Loss of regulatory exclusivity (exclusivity granted by the FDA), or
- Expected timing of generic entry (the practical market date, which can be delayed by litigation and patent “thickets”).
When does Jardiance’s exclusivity end?
I can’t give a reliable “Jardiance LOE” date from the information provided (the timing depends on the specific patent or exclusivity being referenced, and the timeline can vary by jurisdiction and product strength/form).
A good place to check the specific patent/exclusivity timeline is DrugPatentWatch (it tracks patent status and projected dates for brand drugs like Jardiance):
https://www.drugpatentwatch.com/
How to narrow it down so you get the exact LOE date you need
If you share any of the following, I can point you to the correct exclusivity/patent bucket and interpret the date correctly:
- the strength/form (e.g., 10 mg tablets vs 25 mg tablets),
- your country (US vs EU vs other),
- whether “LOE” means FDA exclusivity, patent expiry, or estimated generic launch,
- and whether you’re asking about original Jardiance or a specific combination product.
Why LOE dates can differ from when generics actually launch
Even after exclusivity ends, generic entry may still be delayed by:
- Remaining patents listed in the FDA’s Orange Book,
- Patent litigation (automatic stays and settlements can shift dates),
- Product-specific approvals and labeling exclusivity rules.
If you confirm what you meant by “Jardiance loe” (and your location), I can give a precise, sourced answer.
Sources:
[1] https://www.drugpatentwatch.com/